PT  - JOURNAL ARTICLE
AU  - Yota Fujimura
AU  - Yasuyuki Kimura
AU  - Fabrice G. Siméon
AU  - Leah P. Dickstein
AU  - Victor W. Pike
AU  - Robert B. Innis
AU  - Masahiro Fujita
TI  - Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, <sup>18</sup>F-PBR06, to Image Translocator Protein (18 kDa)
AID  - 10.2967/jnumed.109.068064
DP  - 2010 Jan 01
TA  - Journal of Nuclear Medicine
PG  - 145--149
VI  - 51
IP  - 1
4099  - http://jnm.snmjournals.org/content/51/1/145.short
4100  - http://jnm.snmjournals.org/content/51/1/145.full
SO  - J Nucl Med2010 Jan 01; 51
AB  - As a PET biomarker for inflammation, translocator protein (18 kDa) (TSPO) can be measured with an 18F-labeled aryloxyanilide, 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline (18F-PBR06), in the human brain. The objective of this study was to estimate the radiation absorbed doses of 18F-PBR06 based on biodistribution data in humans. Methods: After the injection of 18F-PBR06, images were acquired from head to thigh in 7 healthy humans. Urine was collected at various time points. Radiation absorbed doses were estimated by the MIRD scheme. Results: Moderate to high levels of radioactivity were observed in organs with high densities of TSPO and in organs of metabolism and excretion. Bone had low levels of radioactivity. The effective dose was 18.5 μSv/MBq. Conclusion: The effective dose of 18F-PBR06, compared with other 18F radioligands, was moderate. This radioligand had negligible defluorination, as indirectly assessed by bone radioactivity. Doses to the gallbladder wall and spleen may limit the amount of permissible injected radioactivity.